



sequanamedical



Innovators in management of
fluid imbalance disorders

liver disease - malignant ascites - heart failure

Swiss Medtech Day – 6 June 2019

Ian Crosbie, CEO

Disclaimer

Important Notice

IMPORTANT: You must read the following before continuing. The following applies to this document, the oral presentation of the information in this document by Sequana Medical NV (the "Company") or any person on behalf of the Company, and any question-and-answer session that follows the oral presentation:

- This presentation has been prepared by the management of the Company. It does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any securities of the Company or any member of its group nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of the Company or any member of its group, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Prospective investors are required to make their own independent investigations and appraisals of the business and financial condition of the Company and the nature of its securities before taking any investment decision with respect to securities of the Company. This presentation is not a prospectus or offering memorandum.
- The information included in this presentation has been provided to you solely for your information and background and is subject to updating, completion, revision and amendment and such information may change materially. No person is under any obligation or undertaking to update or keep current the information contained in this presentation and any opinions expressed in relation thereto are subject to change without notice. No representation or warranty, express or implied, is made as to the fairness, accuracy, reasonableness or completeness of the information contained herein. Neither the Company nor any other person accepts any liability for any loss howsoever arising, directly or indirectly, from this presentation or its contents.
- The presentation also contains information from third parties. Third party industry publications, studies and surveys may also contain that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company reasonably believes that each of these publications, studies and surveys has been prepared by a reputable source, the Company, or any of their respective parent or subsidiary undertakings or affiliates, or any of their respective directors, officers, employees, advisers or agents have independently verified the data contained therein. Thus, while the information from third parties has been accurately reproduced with no omissions that would render it misleading, and the Company believes it to be reliable, the Company cannot guarantee its accuracy or completeness. In addition, certain of the industry and market data contained in this presentation comes from the Company's own internal research and estimates based on the knowledge and experience of the Company's management in the market in which the Company operates. While the Company reasonably believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice. Accordingly, undue reliance should not be placed on any of the industry, market or competitive position data contained in this presentation.
- This presentation includes forward-looking statements that reflect the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results, condition, performance, prospects, growth, strategies and the industry in which the Company operates. These forward-looking statements are subject to risks, uncertainties and assumptions and other factors that could cause the Company's actual results, condition, performance, prospects, growth or opportunities, as well as those of the markets it serves or intends to serve, to differ materially from those expressed in, or suggested by, these forward-looking statements. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. The Company cautions you that forward-looking statements are not guarantees of future performance and that its actual results and condition and the development of the industry in which the Company operates may differ materially from those made in or suggested by the forward-looking statements contained in this presentation. In addition, even if the Company's results, condition, and growth and the development of the industry in which the Company operates are consistent with the forward-looking statements contained in this presentation, those results or developments may not be indicative of results or developments in future periods. The Company and each of its directors, officers and employees expressly disclaim any obligation or undertaking to review, update or release any update of or revisions to any forward-looking statements in this presentation or any change in the Company's expectations or any change in events, conditions or circumstances on which these forward-looking statements are based, except as required by applicable law or regulation.
- This document and any materials distributed in connection with this document are not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of, or located in, any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe any such restrictions.
- The Company's securities have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration under the Securities Act or exemption from the registration requirement thereof.
- By attending the meeting where this presentation is presented or by accepting a copy of it, you agree to be bound by the foregoing limitations.

Commercial stage medtech


Positioned for growth



alfapump®

Proven step change in liver refractory ascites and malignant ascites.

Over 700 devices implanted; reimbursed in Switzerland & Germany; US / Canadian pivotal study commences H2 2019.



alfapump® DSR

Breakthrough approach to fluid overload in heart failure built on proven device platform.

Clinical proof of concept for DSR; first in human **alfapump** DSR study planned for H2 2019.



1913 DGVS
Deutsche Gesellschaft für
Gastroenterologie,
Verdauungs- und
Stoffwechselkrankheiten

**FDA Breakthrough Device
Designation**

alfapump® platform

Unique capabilities to manage fluid imbalance



Pump volume easily adjusted



Fully implantable



No significant heating during charging and operation



Moves up to 4 litres of fluid per day



Long-term implantation & catheter patency



Smart Charger



Programmer



Remote data monitoring



Battery charged through the skin



Easy implantation



Automatic operation




Virtually non-clogging

Strong IP barriers through extensive patent portfolio & know-how

Focus on liver disease and heart failure


Large and growing markets driven by unhealthy lifestyles and ageing populations




Source 1: Centres for Disease Control and Prevention (CDC)
 Source 2: Mozzafarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2017 update (adults: >=20 years of age)

alfapump[®] – clinically validated system

Over 700 implanted systems and over 400 years of clinical experience




alfapump® DSR – building on our proven system



 **alfa** pumpDSR

Three platforms for growth

Balancing risk and reward



Source 1: Management estimate that is inclusive of estimated growth in prevalence of NASH for the US and EU5 based on GlobalData Epidemiology Forecast to 2026. Assumes 1/3 of existing market is due to hepatitis and will become negligible within the next 10 to 20 years.
 Source 2: Management estimate based on WHO cancer incidence rates (2018) and Ayantunde & S. L. Parsons. Annals of Oncology 2007.
 Source 3: GlobalData Heart Failure Epidemiology Forecast to 2026; Costanzo et al. (2007).

Strong newsflow in 2019

Key anticipated milestones

H2 2018

- ✓ Completion of DSR study in pig heart failure model & presentation of results
- ✓ Presentation of clinical data on 17 malignant ascites patients in retrospective clinical study
- ✓ Outcome of NICE review of **alfapump**®
- ✓ Initiation of First in Human clinical study for heart failure, single dose
- ✓ Initiation of TOPMOST: European “Super Registry” (Reporting Data Regularly)

H1 2019

- ✓ Outcome of FDA Breakthrough Device designation
- ✓ Inclusion in German treatment guidelines (DGVS) for complications of liver cirrhosis
- ✓ Completion and presentation of results for First in Human DSR study, single dose
 - Initiation of prospective malignant ascites study
 - Initiation of prospective albumin study

H2 2019

- Initiation of POSEIDON North-American pivotal study
- Expected Dutch reimbursement of **alfapump**®
- Presentation of initial results for First in Human heart failure study, repeated dose with **alfapump**® DSR